Does angiogenesis play a role in the establishment of mesial temporal lobe epilepsy?

Ruba Benini1, Raquel Roth2, Zehra Khoja2

  • 1Division of Pediatric Neurology, Department of Pediatrics, Montreal Children's Hospital, Canada.

Insights

Blocking angiogenesis prevents seizures and hippocampal atrophy in a rat model of mesial temporal lobe epilepsy (MTLE). This finding suggests anti-angiogenesis therapies could treat epilepsy.

Area of Science:

  • Neuroscience
  • Epileptology
  • Vascular Biology

Background:

  • Mesial temporal lobe epilepsy (MTLE) is a common focal epilepsy often linked to hippocampal sclerosis.
  • Angiogenesis, the formation of new blood vessels, is implicated in epilepsy development.

Purpose of the Study:

  • To investigate if blocking angiogenesis prevents seizures and hippocampal atrophy in the pilocarpine rat model of MTLE.
  • To assess the role of angiogenesis in the development of epilepsy-associated brain damage.

Main Methods:

  • Rats were treated with sunitinib, an angiogenesis inhibitor, or a sham treatment after pilocarpine-induced insult.
  • Continuous video monitoring identified seizure development.
  • Histological analysis assessed hippocampal atrophy and angiogenesis (endothelial cell counts).

Main Results:

  • Sunitinib-treated rats did not develop seizures, unlike sham-treated rats.
  • Sham-treated rats showed significant hippocampal atrophy and increased endothelial cell counts.
  • Sunitinib treatment prevented both seizures and hippocampal atrophy, with reduced endothelial cell counts.

Conclusions:

  • Blocking angiogenesis immediately after the initial insult prevents the development of clinical seizures in the pilocarpine rat model.
  • Inhibition of angiogenesis effectively prevents subsequent hippocampal atrophy and seizure development in MTLE.
  • Targeting angiogenesis represents a potential therapeutic strategy for treating MTLE.

Related Concept Videos